A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
MK-4830-001
Phase 1 Completed
470 enrolled
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1 Completed
829 enrolled 100 charts
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Phase 1 Completed
518 enrolled
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
240 enrolled
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Phase 1 Completed
65 enrolled 32 charts
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Phase 1 Completed
20 enrolled 14 charts
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
Phase 1 Completed
169 enrolled
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Completed
43 enrolled 21 charts
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Phase 1 Completed
53 enrolled 15 charts
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Phase 1 Withdrawn
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Phase 1 Completed
102 enrolled 48 charts
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Phase 1 Completed
12 enrolled 18 charts
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
Phase 1 Terminated
75 enrolled
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed